Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia

  • Minimal residual disease (MRD) is the strongest predictor of relapse in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). In BLAST study (NCT01207388), adults with BCP-ALL in remission with MRD after chemotherapy received blinatumomab, a CD19 BiTE® immuno-oncotherapy, 15 µg/m2/day for up to four 6-week cycles (4 weeks continuous infusion, 2 weeks off). Survival was evaluated for 110 patients, including 74 who received HSCT in continuous complete remission. With a median follow-up of 59·8 months, median survival (months) was 36·5 (95% CI: 22.0–not reached [NR]). Median survival was NR (29.5–NR) for complete MRD responders (n = 84) and 14.4 (3.8–32.3) for MRD non-responders (n = 23; p = 0.002); after blinatumomab and HSCT, median survival was NR (25.7–NR) (n = 61) and 16.5 (1.1–NR) (n = 10; p = 0.065), respectively. This final analysis suggests complete MRD response during blinatumomab treatment is curative. Post-hoc analysis of study data suggests while post blinatumomab HSCT may be beneficial in appropriate patients, long-term survival without HSCT is also possible.
Author:Nicola Gökbuget, Gerhard Zugmaier, Hervé Dombret, Anthony Stein, Massimiliano Bonifacio, Carlos Graux, Christoph Faul, Monika Brüggemann, Kate Taylor, Noemi Mergen, Albrecht Reichle, Heinz August Horst, Violaine Havelange, Max S. Topp, Ralf C. Bargou
Parent Title (English):Leukemia and lymphoma
Publisher:Taylor & Francis Group
Place of publication:London [u.a.]
Document Type:Article
Date of Publication (online):2020/07/03
Date of first Publication:2020/07/03
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Release Date:2022/03/07
Tag:Acute lymphoblastic leukemia; allogeneic hematopoietic stem cell transplantation; blinatumomab; immuno-oncotherapy; minimal residual disease
Page Number:9
First Page:2665
Last Page:2673
This trial was funded by Amgen Inc. Qualified researchers may request data from Amgen clinical trials. Complete details are available at Xiaoyu Dong (Amgen Inc.) supported the data analyses. Jonathan Latham of PharmaScribe, LLC (on behalf of Amgen Inc.) and Beatrice Chiang, an employee of Amgen Inc, provided medical writing and editing assistance. Robert Dawson of CACTUS Communications Inc. (on behalf of Amgen Inc.) edited and formatted the figures.
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Licence (German):License LogoCreative Commons - Namensnennung-Nicht kommerziell - Keine Bearbeitung 4.0